Infectious Knockdown of CREB and HIF-1 for the Treatment of Metastatic Uveal Melanoma.
CREB
HIF-1
metastasis
replication competent retroviral (RCR) vectors
therapy
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jul 2019
26 Jul 2019
Historique:
received:
27
05
2019
revised:
17
07
2019
accepted:
17
07
2019
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
31
7
2019
Statut:
epublish
Résumé
Uveal melanoma (UM) is the most prevalent primary intraocular cancer in adults. Up to half the patients develop metastases that are currently incurable, and most patients die within two years following the diagnosis of metastases. Therefore, novel therapeutic approaches are required. It has been established that tumor cells are more resistant to the hypoxia cue than non-malignant cells and can remain viable in hypoxia. Oxygen absence in hypoxic tumor areas means the absence of chemotherapeutics and the absence of the effector for radiotherapy (free oxygen radicals). To overcome this treatment resistance, we constructed MuLV-based replication-competent retroviral (RCR) vectors expressing shRNA targeting the hypoxia-response regulating genes
Identifiants
pubmed: 31357444
pii: cancers11081056
doi: 10.3390/cancers11081056
pmc: PMC6721386
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Israel Science Foundation
ID : 2018-15
Organisme : Israel Innovation Authority
ID : Nofar
Organisme : Ministry of Science and Technology, Israel
ID : 3-15709
Références
Hum Gene Ther. 2001 May 20;12(8):921-32
pubmed: 11387057
Melanoma Res. 2001 Dec;11(6):601-9
pubmed: 11725206
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Cancer Sci. 2003 Dec;94(12):1021-8
pubmed: 14662015
Cancer Res. 2004 Feb 15;64(4):1338-46
pubmed: 14973073
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Eye (Lond). 2008 Jul;22(7):948-52
pubmed: 17363922
Am J Ophthalmol. 2009 Jul;148(1):119-27
pubmed: 19375060
Invest Ophthalmol Vis Sci. 2010 May;51(5):2329-37
pubmed: 20042655
Mol Cell. 2010 Oct 22;40(2):294-309
pubmed: 20965423
Clin Cancer Res. 2012 Dec 15;18(24):6623-33
pubmed: 22923450
Mol Oncol. 2014 Dec;8(8):1508-20
pubmed: 24994677
Arch Biochem Biophys. 2014 Dec 1;563:79-93
pubmed: 24997364
Tumour Biol. 2014 Dec;35(12):11711-7
pubmed: 25296731
Eye (Lond). 2015 Aug;29(8):1027-35
pubmed: 26248525
Oncotarget. 2016 Apr 5;7(14):17844-53
pubmed: 26910282
Oncotarget. 2016 Jun 7;7(23):35454-65
pubmed: 26934558
Cancer Gene Ther. 2017 Feb;24(2):64-74
pubmed: 27934882
Endocrinology. 2018 Feb 1;159(2):1147-1158
pubmed: 29300939
Biochem Biophys Res Commun. 2018 Jul 2;501(4):885-892
pubmed: 29763606
Ocul Oncol Pathol. 2018 Apr;4(3):145-151
pubmed: 29765944
Oncotarget. 2018 May 25;9(40):26096-26108
pubmed: 29899845
Clin Cancer Res. 2019 Apr 1;25(7):2206-2218
pubmed: 30563937
Oncotarget. 2019 Apr 30;10(32):3066-3083
pubmed: 31105886
Ophthalmology. 1993 Sep;100(9):1389-98
pubmed: 8371929
Int J Cancer. 1997 Nov 14;73(4):470-8
pubmed: 9389558
Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):711-5
pubmed: 9845082